<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871325</url>
  </required_header>
  <id_info>
    <org_study_id>TU100CPT1</org_study_id>
    <nct_id>NCT00871325</nct_id>
  </id_info>
  <brief_title>Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans</brief_title>
  <official_title>Effect of Gastrointestinal Nerve Modulation With DAIKENCHUTO (TU-100) on Gastrointestinal and Colonic Transit in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tsumura USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tsumura USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the dose related effects of orally administered
      TU-100, a botanical agent that modulates gastrointestinal nerves, on gastrointestinal
      motility and colonic transit of solids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying of solid</measure>
    <time_frame>1 hr, 2 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 8 hrs, 24 hrs, 48 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Colonic geometric center at 24 hours</measure>
    <time_frame>4 hrs, 8 hrs, and 24 hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ascending colon emptying</measure>
    <time_frame>1 hr, 2 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 8 hrs, 24 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonic geometric center at 4 hours and 48 hours</measure>
    <time_frame>1 hr, 2 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 8 hrs, 24 hrs, 48 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic filling at 6 hours</measure>
    <time_frame>1 hr, 2 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postoperative Ileus</condition>
  <arm_group>
    <arm_group_label>Daikenchuto (TU-100) 7.5g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daikenchuto (TU-100) 2.5g TID (7.5g/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daikenchuto (TU-100) 15g/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daikenchuto (TU-100) 5g TID (15g/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daikenchuto (TU-100)</intervention_name>
    <description>Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.</description>
    <arm_group_label>Daikenchuto (TU-100) 7.5g/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daikenchuto (TU-100)</intervention_name>
    <description>Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.</description>
    <arm_group_label>Daikenchuto (TU-100) 15g/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is willing and able to provide written informed consent

          -  Males and non-pregnant, non-breastfeeding females;

          -  Subject is willing to undergo multiple radionuclide scans

          -  Subject BMI is between 18 and 35 kg/m2

          -  Subject has a negative urine drug screen

          -  Subject has screening laboratory values that are within normal range for the analyzing
             laboratory

        Exclusion Criteria:

          -  Structural or metabolic diseases/conditions that affect the gastrointestinal system,
             or functional gastrointestinal disorders.

          -  Unable to withdraw medications 48 hours prior to the study:

          -  Alter GI transit including laxatives, magnesium or aluminum-containing antacids,
             prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants,
             SSRI and newer antidepressants.

          -  Analgesic drugs including opiates, NSAID, COX 2 inhibitors

          -  GABAergic agents

          -  Benzodiazepines

        NOTE: Low stable doses of thyroid replacement, estrogen replacement, low dose aspirin for
        cardioprotection and birth control pills or depot injections are permissible.

          -  Female subjects who are pregnant or breast feeding.

          -  Clinical evidence (including physical exam, hemoglobin level and review of the medical
             history) of significant cardiovascular, respiratory, renal, hepatic, pulmonary,
             gastrointestinal, hematological, neurological, psychiatric, or other disease that
             interfere with the objectives of the study.

          -  History of allergic reactions to ginseng, ginger, and Sichuan pepper.

          -  History of lactose intolerance.

          -  Subjects who are considered by the investigator to be alcoholics not in remission or
             known substance abusers.

          -  Subjects who have participated in another clinical study within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic, Rochester Methodist CRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester Methodist CRU</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <disposition_first_submitted>December 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 31, 2012</disposition_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric emptying</keyword>
  <keyword>Small bowel transit</keyword>
  <keyword>Colonic transit</keyword>
  <keyword>Whole gut transit</keyword>
  <keyword>Postoperative Ileus</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

